Document is current
Any future updates will be listed below
-
Authors
Röcken, Christoph https://orcid.org/0000-0002-6989-8002
Höhn, Anne Kathrin
Neumann, Jens https://orcid.org/0000-0001-9200-441X
Schildhaus, Hans-Ulrich https://orcid.org/0000-0002-9856-7050
Singer, Stephan https://orcid.org/0000-0003-4775-6609
Clauditz, Till S.
Quaas, Alexander
Jöhrens, Korinna
-
Funding
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Kiel
- License Information
-
More Information
Article History
Received: 4 March 2025
Revised: 8 May 2025
Accepted: 30 May 2025
First Online: 28 June 2025
Declarations
:
: No patient participation was required. The study utilized formalin-fixed paraffin-embedded gastric cancer resection samples obtained by QuIP from a non-commercial supplier blind to patient information. Ethical approval was obtained from the local ethics committee (D593/23 [22.09.2023]) of the University Hospital Schleswig-Holstein, Kiel, Germany.
: CR received honoraria from Alnylam, Astellas, BMS, Janssen, MSD, and Pfizer for lectures and advisory board memberships. AKH, KJ, TSC, and SS have no conflicts to disclose. JN was involved in advisory boards and received honoraria for lectures from Agilent, Astellas, BMS, Boehringer, Falk, MSD, Pierre Fabre, and Roche. H-US is an employee of Discovery Life Sciences and was involved in advisory boards, research, and service projects with pharmaceutical companies as part of this work; payments from Astellas, BMS, Daiichi Sankyo, GSK, MSD, Roche, and Zytomics have been made to the employer. AQ reports payment for lectures by Astellas Pharma, Inc.; travel support for in-office meeting by Astellas Pharma, Inc.; and advisory board participation for Astellas Pharma, Inc.
